Minoryx Therapeutics S.L.

4 trials 1 recruiting Commercial sponsor

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

1 Recruiting

3 Completed trials

4 Countries active

4 Unique IMPs

100% Results reported

Phase III

Phase II

Phase I (Other)

Phase III: 1 Phase II: 2 Phase I (Other): 1

100%

3 of 3 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Adrenoleukodystrophy 3 Rett syndrome 1

Top IMPs

LERIGLITAZONE 4 CARBAMAZEPINE 1 GEMFIBROZIL 1 ITRACONAZOLE 1

All trials

4 total

A clinical study to assess the efficacy and safety of leriglitazone in adult male subjects with cerebral adrenoleukodystrophy. Recruiting

2024-515104-39-00 Phase III 3 countries LERIGLITAZONE
Double-blind, randomized, placebo-controlled study of Leriglitazone in pediatric Rett Syndrome Ended

2024-514684-26-00 Phase II 1 country LERIGLITAZONE
AN OPEN-LABEL, MULTICENTER STUDY IN MALE PEDIATRIC PATIENTS WITH CEREBRAL X-LINKED ADRENOLEUKODYSTROPHY (CALD) TO ASSESS THE EFFECTS OF MIN-… Ended

2024-513774-21-00 Phase II 3 countries LERIGLITAZONE
A PHASE 1, OPENLABEL, SINGLECENTER STUDY TO EVALUATE DRUGDRUG INTERACTIONS WITH GEMFIBROZIL, ITRACONAZOLE, AND CARBAMAZEPINE AND THE FOOD-EF… Ended

2025-521508-23-00 Phase I (Other) 1 country CARBAMAZEPINE; GEMFIBROZIL; ITRACONAZOLE; LERIGLITAZONE

Showing 1–4 of 4 trials

← All sponsors A–Z